TAMPA, Fla. & WORCHESTER, Mass.--(BUSINESS WIRE)--July 31, 2006--Biovest International, Inc. (OTCBB: BVTI - News), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI - News), has received official notification from the Committee on Orphan Medical Products (COMP) of the European Medicines Agency (EMEA;www.emea.eu.int/) that a positive opinion was made regarding the application for orphan medicinal product designation for BiovaxID(TM) the Company's autologous immunotherapy for the treatment of follicular lymphoma in the European Union (EU).
